Your browser doesn't support javascript.
loading
Investigation of chalcogen bioisosteric replacement in a series of heterocyclic inhibitors of tryptophan 2,3-dioxygenase.
Kozlova, Arina; Thabault, Léopold; Dauguet, Nicolas; Deskeuvre, Marine; Stroobant, Vincent; Pilotte, Luc; Liberelle, Maxime; Van den Eynde, Benoît; Frédérick, Raphaël.
Afiliación
  • Kozlova A; Louvain Drug Research Institute (LDRI), Université Catholique de Louvain (UCLouvain), B-1200 Brussels, Belgium; Ludwig Institute for Cancer Research, Brussels B-1200, Belgium; de Duve Institute, UCLouvain, Brussels B-1200, Belgium.
  • Thabault L; Louvain Drug Research Institute (LDRI), Université Catholique de Louvain (UCLouvain), B-1200 Brussels, Belgium; Pole of Pharmacology and Therapeutics, Institut de Recherche Expérimentale et Clinique (IREC), UCLouvain, Brussels B-1200, Belgium.
  • Dauguet N; de Duve Institute, UCLouvain, Brussels B-1200, Belgium.
  • Deskeuvre M; Louvain Drug Research Institute (LDRI), Université Catholique de Louvain (UCLouvain), B-1200 Brussels, Belgium; Pole of Pharmacology and Therapeutics, Institut de Recherche Expérimentale et Clinique (IREC), UCLouvain, Brussels B-1200, Belgium.
  • Stroobant V; Ludwig Institute for Cancer Research, Brussels B-1200, Belgium; de Duve Institute, UCLouvain, Brussels B-1200, Belgium.
  • Pilotte L; Ludwig Institute for Cancer Research, Brussels B-1200, Belgium; de Duve Institute, UCLouvain, Brussels B-1200, Belgium.
  • Liberelle M; Louvain Drug Research Institute (LDRI), Université Catholique de Louvain (UCLouvain), B-1200 Brussels, Belgium.
  • Van den Eynde B; Ludwig Institute for Cancer Research, Brussels B-1200, Belgium; de Duve Institute, UCLouvain, Brussels B-1200, Belgium; Walloon Excellence in Life Sciences and Biotechnology, Brussels B-1200, Belgium.
  • Frédérick R; Louvain Drug Research Institute (LDRI), Université Catholique de Louvain (UCLouvain), B-1200 Brussels, Belgium. Electronic address: raphael.frederick@uclouvain.be.
Eur J Med Chem ; 227: 113892, 2022 Jan 05.
Article en En | MEDLINE | ID: mdl-34678572
ABSTRACT
Selenium is an underexplored element that can be used for bioisosteric replacement of lower molecular weight chalcogens such as oxygen and sulfur. More studies regarding the impact of selenium substitution in different chemical scaffolds are needed to fully grasp this element's potential. Herein, we decided to evaluate the impact of selenium incorporation in a series of tryptophan 2,3-dioxygenase (TDO2) inhibitors, a target of interest in cancer immunotherapy. First, we synthesized the different chalcogen isosteres through Suzuki-Miyaura type coupling. Next, we evaluated the isosteres' affinity and selectivity for TDO2, as well as their lipophilicity, microsomal stability and cellular toxicity on TDO2-expressing cell lines. Overall, chalcogen isosteric replacements did not disturb the on-target activity but allowed for a modulation of the compounds' lipophilicity, toxicity and stability profiles. The present work contributes to our understanding of oxygen/sulfur/selenium isostery towards increasing structural options in medicinal chemistry for the development of novel and distinctive drug candidates.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Medicinas Complementárias: Homeopatia Asunto principal: Selenio / Triptófano Oxigenasa / Calcógenos / Inhibidores Enzimáticos / Compuestos Heterocíclicos Idioma: En Revista: Eur J Med Chem Año: 2022 Tipo del documento: Article País de afiliación: Bélgica

Texto completo: 1 Bases de datos: MEDLINE Medicinas Complementárias: Homeopatia Asunto principal: Selenio / Triptófano Oxigenasa / Calcógenos / Inhibidores Enzimáticos / Compuestos Heterocíclicos Idioma: En Revista: Eur J Med Chem Año: 2022 Tipo del documento: Article País de afiliación: Bélgica